Albumin (human) is under clinical development by Grifols and currently in Phase III for Septic Shock. According to GlobalData, Phase III drugs for Septic Shock have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Albumin (human)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Albumin (human) overview

Human Albumin (Albutein, Plasbumin, albuplan ) is obtained by fractionation of blood plasma. It is formulated as solution for intravenous route of administration. Albutein is indicated for the treatment of hypoalbuminemia, restoration and maintenance of circulating blood volume where it is shown a deficit of volume and use of a colloid is appropriate. Plasbumin is indicated for the treatment of adult respiratory distress syndrome, burns, hypovolemic shock, liver failure. Albutein was under development for kidney transplant.

It is under development for the treatment of amyotrophic lateral sclerosis, Alzheimer's disease, decompensated acute-on-chronic liver cirrhosis, hepatic encephalopathy, septic shock, uncomplicated ascites.

Grifols overview

Grifols is a pharmaceutical and chemical manufacturing company engaged on enhancing the health and well-being of patients worldwide. It is focused on research, development, manufacturing and marketing of plasma-derived therapies, hospital pharmacy products and diagnostic technology for clinical use. It produces plasma derived protein therapies for patients suffering with rare, chronic and life-threatening infections. Grifols offers biological materials for clinical trials, biotechnology research, manufacturing pharmaceutical and diagnostic products. Grifols provides transfusion medicine, hemostasis and immunoassay solutions for blood banks, clinical laboratories and transfusion centers. The company offers its products to hospitals, pharmacies and healthcare professionals. It offers products in the US, Canada, Europe, and Rest of the world. Grifols is headquartered in Barcelona, Spain.

For a complete picture of Albumin (human)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.